Navigation Links
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
Date:1/5/2012

ALBANY, N.Y., Jan. 5, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis' mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis' drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.

BioPontis Alliance has established research alliances with a number of the nation's leading academic-research institutes, in which BioPontis searches for innovative science that has the potential to be translated into new treatments for cancer, neurology, inflammation, and infectious diseases. BioPontis Alliance currently has agreements with a consortium of leading universities and research institutions, including New York University, Columbia University, Memorial Sloan-Kettering Cancer Center, University of Pennsylvania, University of North Carolina (Chapel Hill), University of Virginia, University of Kansas, Oregon Health and Sciences University, Thomas Jefferson University and the University of Florida. In addition to partnerships aimed at identifying early technology, BioPontis has entered into preferred partnership agreements with leading pharmaceutical companies, including Janssen Biotech (wholly owned by Johnson & Johnson), Pfizer and Merck.

AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D. said, "We are pleased to announce this agreement with BioPontis Alliance and to be a part of an innovative and creative business model. Building on the recently announced collaborations with the National Institutes of Health and others, the relationship with BioPontis Alliance is another example of AMRI's leading ability to contribute significant value in the discovery and development of the medicines of the future. Given the outreach by a number of pharmaceutical companies to the outside for innovative new approaches to treating disease, the BioPontis Alliance may fill an important need for the industry in identifying new therapeutic agents and approaches to treating unmet medical needs. We look forward to working with BioPontis Alliance and helping them successfully create value for their partners in academia and pharma, and ultimately for patients."

"We selected AMRI as our anchor CRO for small molecule discovery and CMC services due to their extensive track record over 20 years in supporting the pharmaceutical industry," said Richard A. Basile, CEO and Principal, BioPontis Alliance LLC. "It is important we bring together the best partners to support the success of our new business model. For many reasons, and after significant due diligence, AMRI was the obvious partner of choice. We look forward to working with AMRI and all of our partners in helping to advance some of the new medicines for the future."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization with more than twenty years experience providing customers fully integrated drug discovery, development, and manufacturing services. AMRI supplies a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, AMRI maintains geographic proximity and flexible cost models. AMRI has also historically leveraged its drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. AMRI has successfully partnered certain programs and is actively seeking to out-license its remaining programs to strategic partners for further development.

About BioPontis Alliance LLC

BioPontis Alliance, LLC (BPA) is an asset-based investment capital fund combined with a research and development company   created with established economic and scientific alliances with leading research universities and other institutions that collectively comprise the BioPontis University Alliance (the "University Alliance"). BioPontis Alliance is designed to facilitate efficient access to early-stage innovation by the medical industry, and to manage investment funds that identify, invest in, and develop a portfolio of technologies accessed by BPA through the University Alliance.

 


 


'/>"/>
SOURCE AMRI
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance
2. Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
3. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2011 Results
4. Lotus Pharmaceuticals Announces Business Reorganization and Provides Updates on the Beijing Headquarters Building
5. MediGain Announces Release of New Oncology Analytics Solution
6. Aethlon Medical Announces Biotech Showcase™ 2012 Presentation
7. OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
8. Echo Therapeutics Announces $3.6 Million Warrant Exercises
9. Shield HealthCare Announces Caregiver Story Contest Winners
10. PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer
11. Radient Pharmaceuticals Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Lexmark International, ... solution that connects Lexmark multifunction printers (MFPs) to EDCO ... leading scanning and indexing software solutions for medical records. ... use a Lexmark MFP at the point of care ... facilities reach HIMSS Stage 7 through state-of-the-art ...
(Date:2/21/2017)... IDAHO FALLS, Idaho , Feb. 21, 2017 /PRNewswire/ ... is has completed a private placement with certain investors ... preferred stock of the Company, Series C Convertible Redeemable ... Stock accrues dividends at an annual rate of 6% ... share.  The Company plans to use the proceeds for ...
(Date:2/21/2017)... SAN JOSE, Calif. , Feb. 21, 2017 ... announced that its Cadence ® Tensilica ® Fusion ... HaLow ™ MAC IP offering. The licensable IP targets ... smart city and industrial applications. M2B leveraged the Fusion F1 ... to run value-added applications like voice trigger, audio identification and ...
Breaking Medicine Technology:
(Date:2/21/2017)... Doylestown, Pa. (PRWEB) , ... ... ... leading provider of technology-enabled clinical trial solutions, today announced the further expansion ... types of applications they can leverage as part of Bioclinica’s extensive and ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article ... weight loss. It found that the treatments have led to significant improvements in weight ... to unassisted efforts. It also noted very few problematic results relating to the treatment. ...
(Date:2/20/2017)... ... February 21, 2017 , ... Nancy Johnston Toll marks her debut ... Getting Over the Bump in the Road ” (published by Xlibris). Inspired from her ... cope with the ups and downs experienced by anyone going through cancer treatment and ...
(Date:2/20/2017)... ... February 20, 2017 , ... Researchers at the University of ... well as a marker that may predict response to a particular class of drugs, ... of cancer as well. The new findings were published in Proceedings of the National ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
Breaking Medicine News(10 mins):